Efficacy in Intertriginous Areas
VTAMA cream demonstrated rapid and powerful efficacy across multiple intertriginous areas in a Phase 4, open-label study23,24
In intertriginous areas, VTAMA cream demonstrated rapid and powerful efficacy23
VTAMA cream Efficacy Results at week 1223
82.8% of adult patients (n=29) achieved an iPGA score of 0 (clear) or 1 (almost clear) and at least a 2-grade improvement from baseline at week 12 with a median time of ~6 weeks23
65.5% of adult patients achieved an iPGA score of 0 (clear), which indicates complete clearance at week 12, with a median time of ~8 weeks, with some patients achieving it as early as 2 weeks23
VTAMA cream was well tolerated and demonstrated a safety profile consistent with pivotal studies.23
iPsO Phase 4 Safety Profile2,23
- VTAMA cream was well tolerated with no new safety signals.23
- The most common adverse reactions in the Phase 4 trial were consistent with the Phase 3 most common adverse reactions. In the two Phase 3 pivotal trials, the most common adverse reactions (incidence ≥ 1%) in subjects treated with VTAMA cream were folliculitis, nasopharyngitis, contact dermatitis, headache, pruritus, and influenza.2,23
- Only one trial discontinuation in the Phase 4 trial due to an AE (contact dermatitis).23
- Well tolerated, including in genital areas (n=3), as assessed by investigators.23
75% of adult patients achieved itch relief with ≥4-point improvement in PP-NRS at week 12 (intertriginous areas)24
Patients Achieving a ≥4-point Improvement in PP-NRS by Visit (ITT, OC)*24
*Patients with baseline PP-NRS score of ≥4 who achieved ≥4-point improvement in the PP-NRS from baseline.
Before and After Images
See the significant results from some adult patients using VTAMA cream in this Intertriginous plaque psoriasis Phase 4, open-label study. VTAMA cream helped adult patients with mild, moderate, and severe plaque psoriasis achieve clearer skin. Please note that the photographs you will see are representative of one target lesion on individual patients treated with VTAMA cream during this study.
Retroauricular Folds 1
Age: 66 Gender: Male Patient: 1006-001
Primary Endpoint Success*24,25
Baseline
Physicians Rated‡
iPGA=3
Patient Rated§
DLQI=15
PP-NRS=9
PP-NRS=9
Week 1†
Physicians Rated‡
iPGA=2
Patient Rated§
DLQI=11
PP-NRS=5
PP-NRS=5
Week 12
Physicians Rated‡
iPGA=1
Patient Rated§
DLQI=6
PP-NRS=2
PP-NRS=2
Age: 47 Gender: Male Patient: 1009-003
Primary Endpoint Success*23,25
Baseline
Physicians Rated‡
iPGA=4
Patient Rated§
DLQI=2
PP-NRS=8
PP-NRS=8
Week 4†
Physicians Rated‡
iPGA=2
Patient Rated§
DLQI=1
PP-NRS=4
PP-NRS=4
Week 12
Physicians Rated‡
iPGA=0
Patient Rated§
DLQI=0
PP-NRS=0
PP-NRS=0
Age: 55 Gender: Male Patient: 1002-004
Primary Endpoint Failure*25
Baseline
Physicians Rated‡
iPGA=3
Patient Rated§
DLQI=11
PP-NRS=9
PP-NRS=9
Week 4†
Physicians Rated‡
iPGA=2
Patient Rated§
DLQI=9
PP-NRS=2
PP-NRS=2
Week 12
Physicians Rated‡
iPGA=2
Patient Rated§
DLQI=9
PP-NRS=1
PP-NRS=1
Age: 38 Gender: Male Patient: 1006-008
Primary Endpoint Failure*25
Baseline
Physicians Rated‡
iPGA=3
Patient Rated§
DLQI=6
PP-NRS=7
PP-NRS=7
Week 4†
Physicians Rated‡
iPGA=2
Patient Rated§
DLQI=5
PP-NRS=7
PP-NRS=7
Week 12
Physicians Rated‡
iPGA=2
Patient Rated§
DLQI=4
PP-NRS=5
PP-NRS=5
Age: 44 Gender: Female Patient: 1003-002
Primary Endpoint Success*25
Baseline
Physicians Rated‡
iPGA=3
Patient Rated§
DLQI=3
PP-NRS=1
PP-NRS=1
Week 4†
Physicians Rated‡
iPGA=2
Patient Rated§
DLQI=1
PP-NRS=2
PP-NRS=2
Week 12
Physicians Rated‡
iPGA=1
Patient Rated§
DLQI=1
PP-NRS=3
PP-NRS=3
Age: 39 Gender: Female Patient: 1006-005
Primary Endpoint Success*24,25
Baseline
Physicians Rated‡
iPGA=3
Patient Rated§
DLQI=16
PP-NRS=10
PP-NRS=10
Week 1†
Physicians Rated‡
iPGA=2
Patient Rated§
DLQI=7
PP-NRS=7
PP-NRS=7
Week 12
Physicians Rated‡
iPGA=1
Patient Rated§
DLQI=1
PP-NRS=1
PP-NRS=1
DLQI, Dermatology Life Quality Index; iPGA, Intertriginous Physician Global Assessment; PP-NRS, Patient-Reported Peak Pruritus Numeric Rating Scale.
*Primary endpoint success refers to the primary study endpoint of a patient achieving an iPGA score of 0 or 1 and ≥2-grade improvement from baseline at week 12.
†Patient photos depict a single plaque psoriasis lesion in an intertriginous area at baseline, visit with earliest visible improvement, and at week 12.
‡iPGA is a global efficacy assessment. Example of one representative target lesion of a VTAMA cream-treated patient from the Phase 4, open-label intertriginous plaque psoriasis clinical trial. Individual results may vary. 25
§DLQI and PP-NRS are Patient-Reported Outcomes.
Strictly Necessary Cookies
Previous
